This site is intended for health professionals only

Merck sees profits for 2007 soar

teaser

Merck has posted fourth-quarter profits of almost $5bn as it reaped the benefits of its acquisition of Serono, and the spin-off of its generic drug unit.

The German firm earned $4.9bn in the last three months of 2007, compared with $189m a year earlier.

Sales also increased to $2.6bn in the same period, against $1.75bn in 2006.

The company’s products include the multiple sclerosis drug Rebif (interferon beta 1a), and cancer treatment Erbitux (cetuximab).

Merck chief executive Karl-Ludwig Kley said the results show that the acquisition of Swiss biotech firm Serono was the right decision.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

He added: “For Merck, 2007 was a year of major accomplishments – the successful integration of Serono, the sale of generics and a capital increase, resulting in a very low net debt at year end.

“We produced the strongest financial results in Merck’s long history, allowing us to recommend an increased regular dividend of 1.20 euro ($1.76) and a one-time bonus dividend of two euro ($2.93).”

He added that even “in these uncertain economic times, we expect 2008 will be another year of solid growth for Merck”.

Global sales of Rebif rose 10% in 2007 and 11% in the last quarter, while sales of Erbitux, which it licensed from ImClone Systems, jumped 40% in the year and 33% in the three months.

Copyright © PA Business 2008

Merck






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x